From the results of quantified IC50s of ICAM1 ADCs and Gemcitabine, we found that ICAM1-DXd did not significantly inhibit CCA cells and normal 293T cells in vitro at the set drug concentrations (0–10 μg/mL), while ICAM1-MMAE did potently ablate CCA cells at the highest concentration of 10 μg/mL. The gene discussed is ICAM1; the disease is cholangiocarcinoma.